Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Summary

The study objective is to evaluate the differences, in terms of first occurrence of a skeletal event, in patients with breast cancer and symptomatic bone metastases, when pamidronate is administered during 2 years, or when it is administered during 6 months, followed by a six month rest period, and again a 6 month treatment period.

Timeline

Start

2000-10-18

Primary completion

2004-06-04

Completion

2004-06-04

Drugs

Indications